Illumina buys Jeff Bezos-backed cancer-testing firm Grail in deal worth $8 billion

Gene sequencing company Illumina will pay $8 billion in cash and stock to buy cancer screening startup Grail, the companies said.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.